ibritumomab tiuxetan
- Product Name
- ibritumomab tiuxetan
- CAS No.
- 206181-63-7
- Chemical Name
- ibritumomab tiuxetan
- Synonyms
- Zevalin;Idec-Y2B8;Unii-4Q52C550xk;ibritumomab tiuxetan;Research Grade Ibritumomab;Yttrium 90 ibritumomab tiuxetan;Research Grade Ibritumomab(DHC90703)
- CBNumber
- CB51366991
- Molecular Formula
- C24H35N5O11
- Formula Weight
- 569.5616
- MOL File
- 206181-63-7.mol
N-Bromosuccinimide Price
- Product number
- ATB0010214
- Product name
- IBRITUMOMAB TIUXETAN
- Purity
- 95.00%
- Packaging
- 1G
- Price
- $1143.61
- Updated
- 2021/12/16
- Product number
- ATB0010214
- Product name
- IBRITUMOMAB TIUXETAN
- Purity
- 95.00%
- Packaging
- 2.5G
- Price
- $1771.13
- Updated
- 2021/12/16
- Product number
- ATB0010214
- Product name
- IBRITUMOMAB TIUXETAN
- Purity
- 95.00%
- Packaging
- 5G
- Price
- $2392.33
- Updated
- 2021/12/16
ibritumomab tiuxetan Chemical Properties,Usage,Production
Description
Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin’s lymphoma (NHL). The goal of RIT is to deliver ionizing radiation selectively to tumors while minimizing radiation absorbed in normal tissues.90 Y-lbntumomab tiuxetan is the first commercially available radiolabeled antibody for cancer therapy and more specifically for the treatment of relapsed or refractory low-grade, follicular, or transformed B-cell NHL including patients with rituximab-refractory follicular NHL. lbritumomab is a murine immunoglobulin Gl kappa isotype monoclonal antibody produced in Chinese hamster ovary cells. It targets CD20, a β-lymphocyte antigen. The purified antibody is subsequently reacted with the isothiocyanatobenzyl derivative of DTPA to form ibritumomab tiuxetan. Tiuxetan forms a stable covalent urea type bond with the antibody and can chelate a radionuclide via its five carboxyl groups: either indium-111 for imaging (medium energy gamma emitter) or yttrium-90 for radiotherapy (pure high-energy beta-emitter, mean=0.94 MeV). Rituximab (Rituxane MabThera) is an unlabeled chimeric antibody also directed against CD20. The ZevalinTM therapeutic regimen starts with the imaging protocol: infusion of 250 mg/m2 rituximab to clear peripheral B-cells and improve targeting of radioisotope to tumor cells, followed by 5 mCi 111In-ZevalinTM for whole body imaging to enabie determination of favorable biodistribution of radiolabeled antibody. The therapeutic dose (0.3-0.4 mCi/kg) of 90Y-ZevalinTM is delivered on dfjs 7-9 following another predosing of 250 mg/m2 rituximab. The pure beta-emitting 90Y can be given with few radiation precautions. It has a long path length ‘X90=5 mm) allowing the delivery of a cytotoxic radiation dose to tumor cells more distant to the antibody-bound cell. Its short half-life (64 h) approximates the biological half-life of the radiolabeled antibody (47 h) which may minimize radiotoxicity to nontarget organs. The non tumor distribution is primarily to the bone. In a phase III clinical trial of 143 patients with relapsed or refractory low-grade, follicular, or CD20-positive transformed B-cell NHL, ZevalinTM combined with Rituxan showed an overall response rate (ORR) of 80%, compared to Rituxan alone which gave an ORR of 56%. Also, 30% of ZevalinTM-treated patients achieved complete responses compared to 16% of Rituxan patients. .
Originator
IDEC (US)
Uses
Antineoplastic (monoclonal antibody) [Note—Yttrium-labeled ibritumomab tiuxetan is used for the treatment of non-Hodgkin’s B-cell lymphoma, coadministered with rituximab].
brand name
Zevalin
General Description
Ibritumomab (Zevalin kits to prepare In-111 Zevalin and Y-90 Zevalin, murine) is an MAb derived from an initial sensitizationwith CD20 antigen, expressed on the surface ofnormal and malignant B cells. The antibody is a murineIgG1 κ subtype, directed against CD20 antigen. It is producedin a CHO cell line. Ibritumomab is indicated for useas a multistage regimen to treat patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma, including patients with rituximabrefractoryfollicular non-Hodgkin lymphoma.
Ibritumomab tiuxetan binds specifically to CD20 antigen(human B-lymphocyte–restricted differentiation antigen).CD20 is expressed on pre-B and mature B lymphocytes andon more than 90% of B-cell non-Hodgkin lymphoma. Whenthe CDR of ibritumomab tiutuxan binds to the CD20 antigen,apoptosis is initiated. The tiutuxan chelate binds indium-111and yttrium-90 tightly. Beta emission induces cellular damageby forming free radicals in the target cells and neighboringcells. Tiutuxan is [N-[2-bis(carboxymethyl)amino]-3-(p-isothiocyanatophenyl)propyl]-[N-[2-bis(carboxymethyl)amino]2-(methyl)-ethyl]glycine.
ibritumomab tiuxetan Preparation Products And Raw materials
Raw materials
Preparation Products
ibritumomab tiuxetan Suppliers
- Tel
- 1-(800)-881-8210
- Fax
- 615-250-9817
- inquiries@lgmpharma.com
- Country
- United States
- ProdList
- 2123
- Advantage
- 70
- Tel
- 010-56205725
- Fax
- 010-65763397
- waley188@sohu.com
- Country
- China
- ProdList
- 12335
- Advantage
- 58
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 15971444841
- Fax
- 18327183813
- amber@biochempartner.com
- Country
- China
- ProdList
- 3061
- Advantage
- 58
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9866
- Advantage
- 58
- Tel
- 15002134094
- marketing@targetmol.cn
- Country
- China
- ProdList
- 29431
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58